U.S. drug prices are about four times higher than the combined average drug prices in 11 similar countries, according to a report from the House Ways and Means Committee. The report is based on 2018 pricing for 79 drugs sold in the U.S. and 11 other countries. Drug prices were sometimes 67 times higher in the U.S. Find out what’s being done to lower costs and how Provista can help.
Healthcare organizations are turning to non-opioid medications to help patients manage chronic pain. This helps mitigate the problem of opioid addiction. In some cases, alternatives to opioids actually do a better job of treating the pain. Find out what approaches some doctors and facilities are taking.
Cannabidiol, also known as CBD, is becoming increasingly popular for consumers who want to use it for pain therapy and other medical applications. While interest in CBD and its uses continue to grow, non-acute healthcare providers need more information about its risks and benefits before recommending it to patients as a mainstream treatment.
The Centers for Medicare & Medicaid Services (CMS) Office of the Actuary released its 2018-2027 Projections of National Health Expenditures. Not surprisingly, spending is expected to go up. See how much medical products and services will increase.
Anyone involved in hazardous drug compounding, or shipping or handling hazardous drugs, must wear the proper personal protective equipment (PPE) to guard against exposure to the drugs, drug residue or hazardous drug waste materials. See our eight essential PPE products.
The annual Drug Price Forecast from Vizient®, Provista’s
contracting partner, points to an increase in spend for
pharmaceuticals between Jan. 1 and Dec. 31, 2019. The forecast
predicts pricing for next year and explains the critical issues poised
to affect the cost and use of pharmaceuticals.
Biosimilars are a newer class of drug that hold the potential to alter the healthcare landscape by offering lower prices than originator branded biologics. A biosimilar medicine is a biological medicine that’s almost an identical copy to a licensed biological medicine already in use. It’s been shown to not have any clinically meaningful differences from the original biological medicine in terms of quality, safety and efficacy. So why aren’t more available?
The opioid crisis, now a public health emergency, is challenging non-acute providers to improve opioid stewardship and prescribing practices. At the same time, they must manage the dispensation of opioid alternatives such as high-cost analgesics, whose comparative effectiveness isn’t well understood. This forces providers into a balancing act.